There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

Bain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...

Lupin Share Price: Lupin has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to bolster ...

Lupin's focus on the US portfolio is to increase dollar sales to above $200 million from the earlier range of $170-190 million. Lupin recen...

In an interview to ET, CEO Vinita Gupta said the company had already exited a few products filed from its Somerset facility in New Jersey a...

"India is critical in shaping Lupin's growth story going forward. This acquisition strengthens our position in the Indian market, where we ...

Generic Health, the Australia based wholly-owned subsidiary of Lupin, has entered into a definitive agreement under which Lupin will acquir...

Lupin is bolstering its US branded drugs portfolio with the introduction of Methergine, an oral tablet used to treat postpartum haemorrhage...

Boehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combina...

With no new blockbuster drugs going off patent in the near term, generic pharma companies have to explore new areas of growth like specialt...

A day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...

Lupin signed an agreement with Onset Dermatologics under which it will market the latter's skin disease treatment medicine in US market.

Pharmaceutical firm Lupin said it has received the nod of Drug Controller General of India (DCGI) for IVABRAD tablets, used in the treatmen...